Literature DB >> 28917720

A novel mutation in the JH4 domain of JAK3 causing severe combined immunodeficiency complicated by vertebral osteomyelitis.

Farah Qamar1, Samina Junejo2, Sonia Qureshi2, Michael Seleman3, Wayne Bainter3, Michel Massaad3, Janet Chou3, Raif S Geha3.   

Abstract

JAK3 is a tyrosine kinase essential for signaling downstream of the common gamma chain subunit shared by multiple cytokine receptors. JAK3 deficiency results in T-B+NK- severe combined immune deficiency (SCID). We report a patient with SCID due to a novel mutation in the JAK3 JH4 domain. The function of the JH4 domain remains unknown. This is the first report of a missense mutation in the JAK3 JH4 domain, thereby demonstrating the importance of the JH4 domain of JAK3 in host immunity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  JAK3; Severe combined immunodeficiency

Mesh:

Substances:

Year:  2017        PMID: 28917720     DOI: 10.1016/j.clim.2017.09.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  3 in total

1.  The spectrum of primary immunodeficiencies at a tertiary care hospital in Pakistan.

Authors:  Sonia Qureshi; Fatima Mir; Samina Junejo; Khalid Saleem; Samreen Zaidi; Abdullah B Naveed; Khalil Ahmad; Farah Naz Qamar
Journal:  World Allergy Organ J       Date:  2020-08-05       Impact factor: 4.084

2.  Whole-exome sequencing of T- B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants.

Authors:  R El Hawary; S Meshaal; J Pachlopnik Schmid; A Elmarsafy; A A Mauracher; L Opitz; D Abd Elaziz; S Lotfy; A Eldash; J Boutros; N Galal
Journal:  Clin Exp Immunol       Date:  2020-11-02       Impact factor: 5.732

3.  JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.

Authors:  Gigliola Di Matteo; Maria Chiriaco; Alessia Scarselli; Cristina Cifaldi; Susanna Livadiotti; Silvia Di Cesare; Valentina Ferradini; Alessandro Aiuti; Paolo Rossi; Andrea Finocchi; Caterina Cancrini
Journal:  Mol Genet Genomic Med       Date:  2018-07-21       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.